These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23801885)

  • 1. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.
    Shieh JM; Tang YA; Yang TH; Chen CY; Hsu HS; Tan YH; Salgia R; Wang YC
    Int J Med Sci; 2013; 10(8):988-94. PubMed ID: 23801885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
    Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
    Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.
    Kong LR; Mohamed Salleh NAB; Ong RW; Tan TZ; Syn NL; Goh RM; Fhu CW; Tan DSW; Iyer NG; Kannan S; Verma CS; Lim YC; Soo R; Ho J; Huang Y; Lim JSJ; Yan BJ; Nga ME; Lim SG; Koeffler HP; Lee SC; Kappei D; Hung HT; Goh BC
    Nat Commun; 2020 Mar; 11(1):1556. PubMed ID: 32214092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Contribution of
    Chen GL; Shen TC; Chang WS; Tsai CW; Li HT; Chuang CL; Lai YL; Yueh TC; Hsia TC; Wang SC; Bau DT
    Anticancer Res; 2018 Oct; 38(10):5671-5677. PubMed ID: 30275186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population.
    Liu Y; Zhang Q; Ren C; Ding Y; Jin G; Hu Z; Xu Y; Shen H
    J Biomed Res; 2012 Sep; 26(5):315-8. PubMed ID: 23554766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan.
    Shih CM; Lin PT; Wang HC; Huang WC; Wang YC
    Jpn J Cancer Res; 2000 Jan; 91(1):9-15. PubMed ID: 10744039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
    Vuong HG; Ho ATN; Altibi AMA; Nakazawa T; Katoh R; Kondo T
    Lung Cancer; 2018 Sep; 123():76-82. PubMed ID: 30089599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiRNAs associated polymorphisms in the 3'UTR of MET promote the risk of non-small cell lung cancer.
    Zhu X; Fu C; Zhang L; Xu G; Wang S
    Cell Physiol Biochem; 2015; 37(3):1159-67. PubMed ID: 26402720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis.
    Wang YC; Chen CY; Chen SK; Chang YY; Lin P
    Clin Cancer Res; 1999 Jan; 5(1):129-34. PubMed ID: 9918210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
    Chen YT; Chang JW; Liu HP; Yu TF; Chiu YT; Hsieh JJ; Chen YT; Chen YR; Wu HD; Huang SF
    J Thorac Oncol; 2011 Dec; 6(12):2027-35. PubMed ID: 22052229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.
    Gumustekin M; Kargi A; Bulut G; Gozukizil A; Ulukus C; Oztop I; Atabey N
    Pathol Oncol Res; 2012 Apr; 18(2):209-18. PubMed ID: 21779788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
    Song Z; Wang X; Zheng Y; Su H; Zhang Y
    Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer.
    Kim IH; Lee IH; Lee JE; Hong SH; Kim TJ; Lee KY; Kim YK; Kim SJ; Sung SW; Park JK; Yoo IR; Kim YS; Kim JO; Kang JH
    Clin Lung Cancer; 2016 Sep; 17(5):e31-e43. PubMed ID: 26992846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
    Al-Saad S; Richardsen E; Kilvaer TK; Donnem T; Andersen S; Khanehkenari M; Bremnes RM; Busund LT
    PLoS One; 2017; 12(7):e0181527. PubMed ID: 28742836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.
    Lee S; Kim Y; Sun JM; Choi YL; Kim JG; Shim YM; Park YH; Ahn JS; Park K; Han JH; Ahn MJ
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1203-11. PubMed ID: 21626008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.